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Abstract: Transdermal testosterone gels were first introduced in the US in 2000. Since then, 
they have emerged as a favorable mode of testosterone substitution. Serum testosterone levels 
reach a steady-state in the first 24 hours of application and remain in the normal range for the 
duration of the application. This pharmacokinetic profile is comparable to that of testosterone 
patch but superior to injectable testosterone esters that are associated with peaks and troughs with 
each dose. Testosterone gels are as efficacious as patches and injectable forms in their effects on 
sexual function and mood. Anticipated increases in prostate-specific antigen with testosterone 
therapy are not significantly different with testosterone gels, and the risk of polycythemia is 
lower than injectable modalities. Application site reactions, a major drawback of testosterone 
patches, occur less frequently with testosterone gels. However, inter-personal transfer is a 
concern if appropriate precautions are not taken. Superior tolerability and dose flexibility make 
testosterone gel highly desirable over other modalities of testosterone replacement. Androgel 
and Testim, the two currently available testosterone gel products in the US, have certain brand-
specific properties that clinicians may consider prior to prescribing.
Keywords: testosterone gel, Androgel, Testim, hypogonadism
Physiology of hypothalamic–pituitary–gonadal axis
Testicular function is dependent on the hypothalamic secretion of gonadotropin-releasing 
hormone (GnRH) which in turn stimulates the secretion of follicle-stimulating hor-
mone (FSH) and luteinizing hormone (LH) from the pituitary to act on the testis. This 
results in spermatogenesis and testosterone production via stimulation of seminiferous 
tubules and Sertoli cells, and Leydig cells, respectively. Testosterone is secreted at 
adult levels during three periods of male life: transient surge during the first trimester 
of intrauterine life, perinatal surge during early neonatal life, and continually after 
puberty to maintain androgenization. Testosterone exerts negative feedback both at the 
level of the hypothalamus and the pituitary gland. Additionaly, sertoli cells produce 
inhibin that exerts a negative feedback on FSH secretion.
Diagnosis of androgen deficiency
The estimates of the prevalence of androgen deficiency, defined solely in terms of serum 
testosterone concentrations below the lower limit of the normal range for healthy young 
men, vary greatly among different studies. Longitudinal data from the Massachusetts 
Male Aging Study (MMAS) indicate that the prevalence of symptomatic androgen 
deficiency (Total testosterone 300 ng/dL) in men aged between 40–69 years is between 
6% and 12%.1 In the Baltimore Longitudinal Study of Aging (BLSA), the prevalence 
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of low total testosterone levels (testosterone 325 ng/dL) 
increased from relatively low levels for men aged less than 
49 years to 12%, 19%, 28%, and 49% in men in their 50’s, 
60’s, 70’s, and 80’s, respectively.2 Cross-sectional data 
from the Boston Area Community Health (BACH) Survey 
estimate the prevalence of symptomatic androgen deficiency 
(testosterone 300 ng/dL and free testosterone 5 ng/dL) 
to be 5.6% in men aged between 30 and 79 years.3
Androgen deficiency is a clinical syndrome complex 
that comprises symptoms and signs in conjunction with 
biochemical evidence of testosterone deficiency. Several 
professional societies have published guidelines for the 
diagnosis and treatment of androgen deficiency. These include 
the American Association of Clinical Endocrinologists 
(AACE),4 the Endocrine Society,5 the International Society of 
Andrology (ISA), European Association of Urology (EAU), 
European Academy of Andrology (EAA), and the American 
Society of Andrology (ASA).6
According to the Endocrine Society guidelines of 2006, 
diagnosis of androgen deficiency should be made only in men 
with consistent symptoms and signs and unequivocally low 
serum testosterone levels.5 The diagnostic evaluation of men 
with androgen deficiency proceeds in three steps. The first step 
includes evaluation of general health, lifestyle, and the use of 
recreational drugs such as alcohol, marijuana, opiates, and 
cocaine, and exclusion of systemic illnesses or medications 
that might affect testicular function such as cimetidine, 
spironolactone, and glucocorticoids. The second step is the 
measurement of total testosterone level, preferably in the 
morning, using a reliable assay. If the total testosterone level 
is low, this should be confirmed by repeating the measurement 
of morning total testosterone and in some patients 
(eg, obese and elderly men) by calculation or measurement 
of free or bioavailable testosterone. The third step in the 
diagnostic evaluation is to determine whether androgen 
deficiency is the result of a primary testicular dysfunction or 
secondary to a hypothalamic or pituitary disorder. This is best 
accomplished by measurement of serum LH and FSH levels. 
Elevated LH and FSH levels in association with low testos-
terone levels indicate primary testicular failure, while low or 
inappropriately normal gonadotropins in association with low 
testosterone levels indicate either a hypothalamic–pituitary 
defect or a dual defect. Measurements of prolactin and iron 
studies are also important aspects of evaluation.
Several complexities render the application of these 
guidelines into clinical practice difficult. To start with, 
the signs and symptoms of androgen deficiency in 
men are nonspecific and vary with the age of onset of 
androgen deficiency, its severity and duration, associated 
co-morbidities, genetic differences in androgen sensitivity, 
and previous testosterone therapy.5,7,8 Additionally, the 
measurement of serum testosterone levels by commercial 
immunoassays have been fraught with problems. Fortunately, 
liquid chromatography tandem mass spectrometry, widely 
considered gold standard for total testosterone measurement, 
is now being adopted by some commercial labs. The assays 
for the measurement of free or bioavailable testosterone are 
also fraught with problems. Most of the circulating testoster-
one is bound to sex hormone-binding globulin (SHBG) and 
albumin; only 0.5 to 2% of circulating testosterone is free 
which can be measured by equilibrium dialysis. Bioavail-
able testosterone denotes free testosterone plus albumin-
bound testosterone. Bioavailable testosterone is measured 
by the ammonium sulfate precipitation method. Both free 
and bioavailable testosterone concentrations can also be 
calculated from total testosterone, albumin, and SHBG con-
centrations using the law of mass action equations.9,10 The 
Endocrine Society’s Expert Panel concluded that calculation 
of free testosterone concentration from reliably measured 
total testosterone and SHBG using the law of mass action 
equations provides the best approach for the estimation of 
free testosterone concentration.11 Since bioavailable testos-
terone is a multiple of calculated free testosterone value, it 
does not provide any additional information than that derived 
from calculated free testosterone.
History of testosterone therapy
The first historic evidence that testosterone contributed to 
virility came form the early experiment of Berthold in 1849 
when he transplanted testes from roosters in the abdomen of 
capons (castrated roosters) and observed that animals with 
transplanted testes behaved like normal roosters.12 They were 
noted to fight among themselves and showed an inclination 
towards hens. He reported that “these animals remained 
male in regards to voice, reproduction instinct, and growth 
of comb and wattles.” Following Berthold’s observation, 
there were several experiments using testicular extracts. The 
best known are those by Brown–Sequard (1889), when he 
injected testicular extracts from testicles of dogs and guinea 
pigs on himself at the age of 72.13 He claimed “a remarkable 
return of physical strength and endurance, a rejuvenated 
bowel system, and enhanced mental capacity.” Vornoff 
transplanted testes from animals to humans in the 1930’s 
for the purpose of rejuvenation, but the effectiveness of 
his methods was refuted by the Royal Society of London.14 
Further milestones in androgen replacement were made with 
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the isolation of steroidal androgens by Butenandt (1931), 
extraction of testosterone in a crystalline form from bull 
testes by David and colleagues (1935), and the chemical 
synthesis of testosterone by Butenandt and Hanish (1935), 
and Rizica and Wettstein (1935).15 Since testosterone per se 
was ineffective orally due to high first-pass metabolism in 
the liver, the initial forms of replacement was its alkylated 
form: 17α-methyl testosterone. Alternatively, testosterone 
was compressed into pellets and implanted subcutaneously. 
The era of longer acting injectable testosterone esters began 
in the 1950’s and quickly became the preferred modality 
of replacement.16 In the late 1970’s, the orally effective 
testosterone undecanoate became available.17 In the mid 
1990’s, transdermal testosterone patches became available. 
These were applied either to the scrotal18 or nonscrotal skin.19 
In 2000, the first transdermal testosterone gel (Androgel) 
became available for androgen replacement, initially in the 
US, and subsequently in other countries.20 In 2004, an inject-
able form of testosterone undecanoate that demonstrated a 
superior pharmacokinetic profile21 to other injectable prepara-
tions became available in Europe. Testosterone undecanoate 
is currently undergoing clinical trials in the United States. 
In this paper, we will only review the safety and efficacy of 
testosterone gel in the treatment of male hypogonadism.
Testosterone gel
The need for a transdermal testosterone gel arose to overcome 
the drawbacks of the other delivery systems. For instance, 
injectable esters were associated with peaks and troughs of 
serum testosterone outside the physiological range, patches 
were associated with a high incidence of application site reac-
tions, and pellets were associated with the risk of extrusion 
and infection.
The two commercially available forms of testosterone 
gel in the US are Androgel and Testim (1%) gels. Inactive 
ingredients in AndroGel are carbomer 980, ethanol (67.0%), 
isopropyl myristate, purified water, and sodium hydroxide.22 
Inactive ingredients in Testim are purified water, pentade-
calactone, carbopol, acrylates, propylene glycol, glycerin, 
polyethylene glycol, ethanol (74%), and tromethamine.23 
Androgel is available in metered-dose pumps and packets. 
The metered-dose pump delivers 1.25 g of testosterone when 
the lever is fully depressed once. Androgel packets are avail-
able in 2.5 g and 5 g dosing options. Testim gel is available 
as a single dose (tube) containing 5 g of the product.
The recommended starting dose of testosterone gel is 
5 g/day and this provides a nominal delivery of 5 mg/day 
(1%) of testosterone systemically. Serum testosterone levels 
should be monitored serially to ensure proper dosing. If serum 
testosterone concentration is below the normal range or if 
the desired clinical response is not achieved, the dose may 
be increased from 5 g to 7.5–10 g. It is recommended that 
testosterone gel be applied early morning on intact dry skin 
over the shoulders, upper arms or in case of Androgel, the 
abdomen as well. Patients are advised to wash their hands 
well after application, allow the application site to dry 
for a few minutes and to cover the site with clothing. It is 
recommended to wait for four hours prior to showering or 
swimming. Application sites must to be washed with soap 
and water if skin-to-skin contact of these areas is anticipated 
with another person.
Pharmacokinetics of testosterone gel
When an open system of hydroalcoholic gel of a steroid 
is applied to the skin, the steroid is rapidly absorbed into 
the stratum corneum, which forms a reservoir and acts as 
a rate-controlling membrane. The steroid then gradually 
diffuses from this skin reservoir over several hours, reaching 
steady-state levels in the serum.24 In 2000, Androgel became 
available for treatment of male hypogonadism in the US. 
Wang and colleagues20 demonstrated that application of 
10 g/day of Androgel (applied either entirely at one site or at 
four different sites) resulted in a significant increase in serum 
testosterone levels with parallel and appropriate increases in 
serum dihydrotestosterone (DHT) and estradiol (E
2
) levels. 
After the first application of Androgel to hypogonadal men, 
serum testosterone levels rose into the normal range within 
30 min followed by a gradual rise throughout the following 
24 hours (Figure 1). By the end of 1st day, the levels attained 
were comparable with the subsequent steady-state pre-dose 
levels on the 3rd, 5th, and 7th days of application. Mean serum 
testosterone levels were four- to fivefold above the baseline 
levels and at the upper limit of the normal range for the 
duration of gel application (one site: 745.53 ± 149.57 ng/dL; 
four sites: 794.52 ± 118.16), and returned to baseline within 
four days after stopping application. These serum patterns 
were similar, irrespective of the number of sites of applica-
tion. However, the application of testosterone gel at four 
sites resulted in an area under the curve of testosterone 
which was 23% higher compared to application of the same 
amount of gel at one site (although this difference did not 
achieve statistical significance). Swerdloff and colleagues25 
demonstrated long-term pharmacokinetics of 1% Androgel 
in 227 hypogonadal men. Subjects were assigned randomly 
to receive 5 or 10 g of Androgel or two nonscrotal patches. 
After 90 days of gel treatment, the dose was titrated up 
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(5 to 7.5 g) or down (10 to 7.5 g) if the serum testosterone 
levels were outside the normal range. On repeated applica-
tion, mean serum levels of testosterone were maintained in 
the middle normal range with 5 g gel and in the upper normal 
range with the 10 g gel. Pharmacokinetics on days 30, 90, 
and 180 remained remarkably similar and steady levels of 
serum testosterone were maintained. On longer follow up of 
up to 32 months, serum concentrations of total testosterone 
and free testosterone increased dose dependently in the first 
12 months; thereafter, testosterone levels did not appear to 
be different26 (Figure 2).
In 2003, McNicholas and colleagues27 compared the 
response of two doses of 1% Testim (5 or 10 g/day) to 
5 mg/day of Androderm patch in 208 hypogonadal men. 
Consistently throughout the study, Testim 10 g/day increased 
average, minimum, and maximum concentrations (C
avg
, C
min
, 
and C
max
) more than both 5 g/day dose and Andropatch. 
At 90 days, the mean change from baseline with 10 g/day 
Testim was over three times greater than that with Andropatch 
(P  0.001) and about twice as high as the 5 g/day Testim 
(P  0.05). The results at 30 and 60 days were consistent with 
those at 90 days. The dose-dependent improvements in all 
pharmacokinetic profiles of testosterone gel in comparison to 
testosterone patch have been replicated in other studies.28–31
In a open-label crossover study of 30 hypogonadal 
men with human immunodeficiency virus (HIV), Scott 
and colleagues32 compared the response between weekly 
intramuscular (IM) testosterone (100–200 mg/week) and 
1% Androgel (5–10 g/day) for eight weeks. Peak levels of 
serum-free testosterone concentrations were significantly 
greater after IM testosterone (42 pg/mL) than after Androgel 
(23 pg/mL) (P  0.001). In addition, the peak-trough 
fluctuation in free testosterone was significantly greater after 
IM (26.7 ± 12.8 pg/mL) than Androgel (2.7 ± 10.2 pg/mL; 
P  0.001). The percentage of patients who achieved thera-
peutic serum concentrations was 50% during IM and 83% 
during Androgel therapy.
A randomized, crossover study was performed by 
Marbury and colleagues33 to compare the pharmacokinetic 
profiles of Testim and Androgel. Twenty-nine hypogonadal 
subjects received a single dose (5 g) of each formulation 
seven days apart. C
max
 estimates for total testosterone, free 
testosterone, and dihydrotestosterone were greater (30%, 
38%, and 19%, respectively) following the application of 
Testim compared to Androgel. Similarly, area under the 
curve (AUC; 0–24) estimates for total testosterone, free 
testosterone, and dihydrotestosterone were greater (30%, 
47%, and 11%, respectively) following the application of 
Testim compared to Androgel.
In summary, the pharmacokinetic profile and the dose 
proportionality observed after testosterone gel application 
indicate that this transdermal delivery system raises serum 
testosterone levels into mid-high normal adult male range in 
a uniform and predictable manner. However, since inter- and 
intraindividual variations exist, it is prudent to monitor serum 
testosterone levels serially.
Figure 1 Serum T concentrations (mean ± SEM) over 24 h after first application of 100 mg T gel. Reproduced with permission from Wang C, et al.  J Clin Endocrinol Metab. 
2000;85:964–969. © The endocrine Society.
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Therapeutic efficacy
The effects of testosterone gel on outcomes such as body 
composition, bone mineral density (BMD), sexual function, 
and cognition have been studied in several intervention trials 
(Table 1).
Body composition
The mechanisms by which hormones influence body com-
position, muscle strength, and physical performance are only 
partly understood. Possible biological mechanisms include 
the effects of testosterone on regulation of mesenchymal 
stem cell differentiation34,35 and muscle protein synthesis36,37 
through androgen receptor-mediated pathways.35 Testosterone 
could also indirectly affect body composition through its 
effects on various inflammatory pathways.38–41
Wang and colleagues42 showed that after 90 days of 
treatment with 1% Androgel (5 or 10 g/day) or Androderm 
(5 mg/day), lean body mass (LBM) increased in all groups. 
However, the highest gains were seen in the 10 g/day group. 
Furthermore, reduction in fat mass (FM) and percent fat was 
only seen in the testosterone gel groups. On day 180, the 
changes in LBM and FM were maintained in the gel and 
patch groups. Similar changes in LBM and FM have been 
replicated in subsequent studies using 1% Testim.27,43 In 
an extension of their former study, Wang and colleagues26 
followed hypogonadal patients receiving Androgel (5, 7.5, 
or 10 g/day) for an additional three years, and showed that 
LBM increased significantly from baseline and was main-
tained throughout the study period. The change in LBM was 
1.97 ± 0.24 kg at six months, which increased to 2.93 ± 0.32 
kg at 18 months and 2.89 ± 0.41 kg at 30 months (P = 0.0065). 
There was a concomitant decrease in FM. The decrease in FM 
was 0.8 ± 0.3 kg at six months, 1.57 ± 0.38 at 18 months, and 
1.30 ± 0.51 kg at 30 months. However, neither LBM nor FM 
change was significantly different among the different dose 
groups nor was there was a significant increase in muscle 
strength (Figure 3).
Bone density
Testosterone may also directly affect bone tissue. Androgen 
receptors have been identified on both the osteoblastic and 
osteoclastic lineages as well as chondrocytes.44,45 Androgens 
Figure 2 Serum T concentrations (mean 6Se) before (day 0) and after transdermal T applications on days 1, 30, 90, and 180. reproduced with permission from Swerdloff rS, 
et al. J Clin Endocrinol Metab. 2000;85:4500–4510. © The endocrine Society.
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exert proapoptotic effects on osteoclasts and antiapoptotic 
effects on osteoblasts and osteocytes. Testosterone also 
modulates the effects induced by other hormones and cyto-
kines involved in bone metabolism.46 Testosterone exerts its 
influence on the (RANK)/osteoprotegerin (OPG) system47 
and helps protect excessive bone resorption.48 Additionally, 
testosterone appears to indirectly limit bone resorption by 
inhibiting the expression of interleukins 1 and 649,50 and cyto-
kines that induce bone resorption by promoting osteoclast 
activation and differentiation. Effects of testosterone on bone 
are also mediated via its conversion to estradiol. However, 
one recent study did not show adverse skeletal consequences 
by inhibiting aromatase by anastrazole.51
A number of randomized placebo-controlled trials, both 
short-term and long-term, of testosterone therapy on bone 
outcomes have been conducted. In a three-month study 
of testosterone replacement with Testim,27 no significant 
BMD changes were observed, which confirms that a longer 
duration of treatment is needed to see considerable changes 
in BMD. Androgel application for six months was shown to 
decrease bone resorption markers and increase osteoblastic 
activity, resulting in a significant increase in BMD at the hip 
and spine.52 In the three-year extension of this study,26 bone 
turnover markers confirmed that in the early phase there was 
a decrease in bone resorption and an increase in bone forma-
tion. However, in the later phase there was no further decrease 
in bone resorption. BMD continued to increase at the hip 
and spine after 6, 18, and 30 months of treatment (Figure 4). 
The long-term effects of Testim have been evaluated in 
open-label extensions of two studies involving a total of 371 
hypogonadal men30 receiving Testim 5 or 10 g daily for up to 
12 months. Analysis of BMD showed that long-term treat-
ment with Testim was associated with an increase in BMD 
that appeared incremental with longer duration of therapy. 
Figure 3 Changes in body composition A) and muscle strength B) during treatment with Androgel. reproduced with permission from wang C, et al. J Clin Endocrinol Metab. 
2004;89:2085–2098. © The endocrine Society.
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Long-term studies investigating the efficacy of testosterone 
gel therapy in reducing fracture risk are lacking.
Sexual function
Androgens have a role in several aspects of male sexual 
behavior such as libido, erectile function, and orgasms.53 
Trials of testosterone gel replacement in hypogonadal men 
are consistent in showing an improvement in sexual function. 
In a one-month study designed specifically to explore the time 
to response in sexual activity after testosterone replacement, 
638 hypogonadal men received 5 or 10 gm/d of Testim gel in 
an open-label fashion.54 After one week of Testim therapy, 
patients showed marked improvements in sexual function that 
continued to improve through week 2 and was maintained at 
week 4. Long-term studies using Androgel replacement in 
hypogonadal men (5 or 10 g/day) showed that sexual func-
tion (sexual desire, motivation, and sexual performance) 
increased in all treatment groups at 30 days and was main-
tained with continued use for three years.26 This and other 
data55,56 suggest that normalization of sexual function occurs 
once testosterone levels are restored to the lower adult male 
concentration range. Increasing serum testosterone levels 
to the upper normal range does not further improve sexual 
function. In a three-month study comparing 10 g Testim with 
Androderm and Andropatch, Steidle and colleagues29 treated 
406 hypogonadal men. There was a significant improvement 
in mean scores for spontaneous erections, sexual motivation, 
sexual desire and sexual performance in men on Testim 
compared to placebo. Improvements in sexual function and 
libido were also evident in another three-month study of 
208 patients.27 Both doses of Testim (5 g/day and 10 g/d) 
produced improvements in spontaneous erections, sexual 
desire, and performance. Additionally, compared to 
Andropatch, treatment with Testim gel was associated with 
more consistent improvements in sexual motivation through-
out the 90-day period, with significant differences from 
baseline at all time points. The benefits of Testim therapy 
on patients’ sexual function were also sustained over 
one year.30
The benefit of testosterone gel as an adjunct therapy 
to sildenafil in men with erectile dysfunction (ED) was 
demonstrated in a study of 75 hypogonadal men with 
confirmed lack of response to sildenafil monotherapy.57 
Testosterone-treated subjects had greater improvement in 
erectile function compared to those who received placebo, 
reaching statistical significance at week 4 (P = 0.029). Similar 
trends were observed for improvements in orgasmic func-
tion, overall satisfaction and International Index of Erectile 
Function (IIEF) score.
Mood
Studies have shown that testosterone levels correlate 
with mood. There is historic evidence of a strong positive 
correlation of testosterone with parameters such as mental 
well being, joyfulness, social interactivity, general arousal 
reaction, and wakefulness. Negative correlations have been 
reported with depression, nervousness, irritability, and 
anxiety.53
Figure 4 Changes in hip and spine bone mineral density (BMD) in hypogonadal men treated with Androgel. reproduced with permission from wang C, et al.   J Clin Endocrinol 
Metab. 2004;89:2085–2098. © The endocrine Society.
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In hypogonadal men receiving Androgel, positive 
mood parameters, such as sense of well being and energy 
level improved while negative parameters such as sadness 
and irritability decreased. The improvement in mood was 
observed on day 30 and was maintained with continued 
treatment for six42 and 36 months.26 The improvement in 
mood parameters was not dependent on the magnitude of 
increase in serum testosterone levels. In fact, once serum 
testosterone increased into the low normal range, maximal 
improvement in mood parameters was seen. Thus, improve-
ment in mood (similar to sexual function) in response to 
testosterone therapy appears to be dependent on reaching a 
threshold of serum testosterone that lies in the low normal 
range. The same results were replicated with the use of Tes-
tim where mood improved early after institution of treatment 
that was maintained for the duration of the treatment up to 
three months27,29 and one year.30 In a short-term study with 
Testim, Loizides and colleagues54 showed that measures of 
positive and negative mood improved significantly, begin-
ning with the first week of therapy and reaching a maximal 
response at the second week. Kuhnert and colleagues28 have 
reported similar findings.
Safety
Application site reactions
The local tolerability of testosterone gel is superior to other 
transdermal products. In studies comparing testosterone 
gel with a testosterone patch, the incidence of adverse skin 
events has been significantly higher in the testosterone patch 
group. For instance, skin irritation was reported in 5.5% of 
subjects treated with Androgel and in 66% of subjects in the 
testosterone patch (Androderm) group in a six-month study 
of 227 hypogonadal men.20
The most commonly reported skin reactions were 
erythema and irritation at the application site. Upon longer 
follow up of approximately four years, skin irritation was 
minimal, did not appear to be dose dependant and was not a 
concerning cause for discontinuation.26 Both short- and long-
term studies using Testim also confirm these findings.27,29,30
Prostate
Long-term treatment with testosterone gel has shown a good 
safety profile with respect to the prostate. In the longest 
published trial of testosterone gel in which 163 hypogonadal 
men were treated for up to 42 months with Androgel,26 
the baseline mean prostate-specific antigen (PSA) level 
was 0.85 ± 0.06 ng/ml. Mean PSA at six months was 
1.11 ± 0.08 ng/ml and showed no significant increase with 
continued testosterone treatment (P = 0.150). Furthermore, 
there was no difference in serum PSA levels among the 
three testosterone gel dose groups (5, 7.5, and 10 g/day). 
Mean international prostate symptom scores (IPPS) were not 
increased in subjects on gels. One subject had transurethral 
resection of the prostate for lower urinary tract symptoms. 
Of the subjects who had elevated PSA during the study, three 
had confirmed prostate cancer on biopsy (all 60 years 
old). In a long-term trial of Testim in 371 hypogonadal 
men (5 and 10 g/day),30 baseline PSA concentrations were 
1.26 ± 0.05 ng/mL. The change from baseline were signifi-
cant at each of the visits (0.39 ng/mL [month 3], 0.37 ng/mL 
[month 6], and 0.45 ng/mL [month 12]). In this study, three 
patients were diagnosed with prostate cancer. Two of them 
were aged 63 and 73 years and underwent biopsies because of 
rising PSA values. The third subject was 53 years old and had 
a biopsy 60 days post-treatment because of an asymmetrical 
prostate on digital exam. Mean IPSS scores were not increased 
from baseline. Although short-term studies27,28,42 using Andro-
gel or Testim have reported no cases of prostate cancer, 
one year30 and three year26 extensions of these studies have 
documented prostate cancer in a small number of subjects. 
In both short and long-term testosterone gel studies, PSA 
elevations of 4 ng/mL or greater have occurred only in a 
minority of individuals and many of them have either had 
normal PSA values on repeat measurements or normalization 
of PSA on discontinuation of testosterone or negative biopsies 
(in subjects who had persistent elevations in PSA despite treat-
ment discontinuation).26–28 Meikle and colleagues showed in 
a one-year study of physiological testosterone replacement 
in hypogonadal men that PSA levels remained within the 
normal range, and that none of the subjects developed benign 
prostatic hyperplasia during therapy.58
There is debate regarding cases of prostate cancer that are 
detected in trials involving long-term testosterone administra-
tion. Close monitoring of PSA in these trials, the heightened 
awareness of the investigators, and the rate of referral to a 
urologist for prostate biopsy be accountable for the increased 
detection of prostate cancer. There is also a concern that tes-
tosterone therapy may unmask asymptomatic occult prostate 
cancer. There still remains considerable uncertainty whether 
testosterone administration can lead to the growth and devel-
opment of prostate cancer or if prostate cancer cases detected 
during therapy are coincidental to treatment.
Hematocrit
Increase in hematocrit (Hct) and hemoglobin (Hb) levels 
in clinical trials of testosterone replacement confirms the 
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decade-old known effects of testosterone on erythropoesis. 
Long-term administration of 1% Androgel (5, 7.5, or 10 g/d) 
for 36 months showed that Hb and Hct levels increased 
steadily until month 12 in a dose-dependent manner with 
the 10 g/d group attaining the highest Hb and Hct concen-
trations.26 After 12 months there was no further increase in 
the levels. In the same study, 9% of men achieved Hb levels 
above 18 g/dl or Hct greater than 56% at some point during 
the study. In a 12-month study of 1% Testim in hypogonadal 
men, mean Hb and Hct values remained within the normal 
range. However, 2.4% of subjects showed an increased hema-
tocrit beyond the acceptable range and were discontinued 
from the study.30 However, none of these studies examined 
if the response profile was significantly different in younger 
and older men.
Skin transfer
There is concern about the possibility of inadvertent interper-
sonal transfer of testosterone gel. In men, the bioavailability of 
applied testosterone gel is limited to 10%–15%. Upon applica-
tion, testosterone penetrates the skin, with alcohol acting as 
a permeation enhancer. When applied to the skin, the alcohol 
evaporates quickly leaving significant amount of testosterone 
on the skin. Hence, a large reservoir of testosterone is left on 
the skin with the potential to be transferred.59 Unpublished 
studies from manufacturers indicate that both Androgel and 
Testim have the potential to raise testosterone levels in women 
after skin contact with treated men even hours after application. 
Additionally with abdominal application of Testim, wearing a 
shirt did not completely prevent the transfer of testosterone to 
the partner in spite of covering the area with a shirt. As of May 
7th 2009, the US Food and Drug Administration (FDA) has 
instructed testosterone gel manufactures to issue a “black box” 
warning regarding the potential for skin-to-skin transfer.60 This 
is a consequence of secondary exposure of children ranging 
in age from nine months to five years that were reported to 
the FDA. Adverse events reported in these children included 
enlargement of the genitalia, premature pubarche, advanced 
bone age, and aggressive behavior. Overall, covering the 
application site with clothing seems to minimize the risk of 
testosterone transfer during skin-to-skin contact. Even though 
there is paucity of cases reporting inter-personal transfer, the 
risk of transfer to women and children is possible. Hence, 
patient education is crucial.
Monitoring treatment
The goal of testosterone therapy should be to restore serum 
testosterone levels to the mid-normal range. In men receiving 
transdermal gel, testosterone level should be measured after 
patient has been on treatment for one to two weeks, ideally 
between two and six hours after gel application. Initial moni-
toring for symptom relief (improvement in libido, erectile 
function, energy and well being) should be performed three 
months after initiation of therapy. Failure to benefit from 
therapy within a reasonable time interval (3–6 months) 
should result in investigation for other causes of symptoms.6 
A baseline BMD should be obtained in all hypogonadal men 
and repeated after one to two years of testosterone therapy 
to assess for interval changes in bone mass.5,6 Hematocrit 
should be measured at baseline, repeated at three months, and 
then annually. The Endocrine Society specifies a hematocrit 
cut-off of 54% above which testosterone therapy should be 
discontinued. If hematocrit rises above this level, testosterone 
therapy should be stopped until hematocrit decreases to a 
safe level. The patient should be evaluated for hypoxia and 
sleep apnea, and therapy should be restarted at a reduced 
dose. A therapeutic phlebotomy at periodic intervals may be 
required in some cases. Digital examination of the prostate 
and PSA measurement should be performed before initiating 
treatment, at three months, and annually thereafter depend-
ing upon the regional practice pattern. PSA increments of 
1.4 ng/mL above baseline in any one-year period should 
warrant urologic evaluation and consideration of prostate 
biopsy. If longitudinal PSA data are available for more than 
two years, PSA velocity can be calculated to assess risk of 
prostate cancer. PSA velocity of more than 0.4 ng/ml/year, 
using the PSA level after six months of testosterone adminis-
tration as the reference, requires further urological evaluation. 
PSA velocity should be used only if there are longitudinal 
PSA data for more than two years.
Androgel versus Testim
Although Androgel and Testim have well-established 
therapeutic efficacies, comparison studies that exist in the 
literature might prompt the provider to use one more than 
the other. Short-term, open-label studies43,61 have demon-
strated that in patients who failed to respond to Androgel, 
their libido, erectile and ejaculatory function, cognition, and 
overall sexual satisfaction significantly improved following 
a switch to Testim. In a larger study, the records of 370 
hypogonadal men on testosterone gel therapy (Testim 
or Androgel) were reviewed to identify men who under-
went a brand substitution due to suboptimal response.62 
Approximately 20% of these 370 men underwent brand 
substitution. Of these, 83% (n = 62) switched from Androgel 
to Testim. The predominant indication for gel substitution 
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was either lack of improvement in symptoms or failure to 
achieve adequate serum levels. Following a change to Testim, 
mean total and free testosterone levels increased significantly 
(Figure 5) with only 17% of patients having total testosterone 
less than 300 ng/dL as compared to 58% while they were on 
Androgel. On the contrary, 17% of men (n = 13) switched 
from Testim to Androgel. The main indication for this sub-
stitution was the physical characteristics (scent and residue) 
of Testim. Following switch to Androgel, total testosterone 
levels remained below 300 ng/dL in 27% of these patients as 
compared to 15% while they were on Testim. These findings 
are probably explained by the differing pharmacokinetics 
of the two testosterone gels. The enhanced absorption of 
Testim is attributed to pentadecalactone, an emollient specific 
to Testim, which also accounts for the unique scent of the 
gel.33 In summary, although Testim appears to have a greater 
bioavailability than Androgel, this advantage is at the expense 
of undesirable physical properties such as its stickiness and 
smell. An easy option for Androgel users not achieving 
adequate serum testosterone levels would be to increase the 
dose rather than switching brands.
Contraindications
Baseline evaluation of hypogonadal men should include 
screening for conditions which could be exacerbated by 
testosterone therapy. Testosterone administration is contra-
indicated in men with prostate or breast cancer. Testosterone 
therapy should not be administered to men with a palpable 
prostate nodule (or induration), or if PSA is greater than 
4 ng/mL (without a urological evaluation). Testosterone 
therapy should be administered carefully to men with benign 
prostatic hypertrophy and mild to moderate lower urinary 
tract symptoms. Men with severe lower urinary tract symp-
toms (IPSS symptom score 19) should undergo urological 
evaluation before consideration of testosterone therapy. 
Baseline assessment of prostate cancer risk is necessary in 
middle-aged and older men before instituting therapy. Age, 
race, family history of prostate cancer and PSA level – the 
major determinants of prostate cancer risk – should be 
factored in this risk assessment.
As testosterone therapy is expected to raise Hct, patients 
with baseline hematocrit 50%5,6 should not be given testos-
terone. Testosterone administration can cause salt and water 
retention and exacerbate edema in men with uncontrolled 
congestive heart failure. Therefore, testosterone should 
not be administered in men with class III or IV congestive 
heart failure. Men with moderate or severe obstructive 
sleep apnea should be evaluated by a sleep specialist before 
testosterone therapy is instituted.
Conclusion
The favorable pharmacokinetic profile and treatment 
outcomes combined with enhanced tolerability and superior 
compliance suggests that testosterone gel formulations are 
a safe and effective treatment in men with hypogonadism. 
Studies suggest that the two commercially available gels, 
Figure 5 Total serum testosterone levels pre- and post-gel substitution. Reproduced with permission from Grober ED, et al. Efficacy of changing testosterone gel preparations 
(Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res. 2008;20:213–217. © Nature Publishing Group.
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Androgel and Testim, are not bioequivalent and that Testim 
may have superior pharmacokinetic properties in comparison 
to Androgel. It appears that a brand substitution may be 
reasonable in nonresponders. While substitution from 
Androgel to Testim may result in higher testosterone levels 
and improved clinical responsiveness, a switch from Testim 
to Androgel may be needed in some subjects to eliminate the 
unwanted side effects related to the physical properties of 
the gel. However, it should be realized that trials comparing 
the efficacy of brand substitution to date have been unblinded. 
This methodological shortcoming compromises the quality 
of the findings as it is not known how much of an effect this 
bias would have on symptom amelioration.
The advantages of testosterone gel over the testosterone 
patch are a lower incidence of skin irritation, the ease of 
application, the invisibility of the gel, and the ability to deliver 
testosterone levels dose-dependently. Transdermal gel also 
gives stable testosterone levels while injectable testosterone 
esters are associated with “roller-coaster” pharmacokinetics 
where serum testosterone levels rise into the high normal or 
supraphysiological range immediately following injection, 
but fall into the hypogonadal range within two weeks.63,64 
This is reflected in fluctuations in mood, energy, and sexual 
function. Injectable testosterone esters also result in a high 
incidence of polycythemia compared with gels due to 
higher circulating testosterone levels. Injectable testoster-
one undecanoate is a long-acting ester that maintains serum 
testosterone levels within the normal range without major 
fluctuations, and its longer half-life allows for administra-
tion every three months after an initial loading dose.65–67 This 
formulation is already in use in Europe and is awaiting FDA 
approval for use in the United States. However, a potential 
adverse effect of testosterone gel that should be borne in mind 
is the transfer risk to children and women upon close contact 
with the skin. Patient education is necessary.
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